Alkyl salicylic acids, overbased detergents derived from alkyl salicylic acids, lubricating compositions including the alkyl salicylic acids and/or overbased detergents, and processes of making and using the same, are described.

Alkyl salicylic acids, overbased detergents derived from alkyl salicylic acids, lubricating compositions including the alkyl salicylic acids and/or overbased detergents, and processes of making and using the same, are described.

Alkyl salicylic acids, overbased detergents derived from alkyl salicylic acids, lubricating compositions including the alkyl salicylic acids and/or overbased detergents, and processes of making and using the same, are described.

The present invention provides a dynamic interface system between an extraction device and a chromatographic purification device for separating and purifying substance(s) from a mixture or matrix. One embodiment is the Supercritical Fluid Interface (“SFI”) between Supercritical Fluid Extraction (“SFE”), and Supercritical Fluid Chromatography (“SFC”). The SFI is capable of interfacing; gas, subcritical and supercritical fluid extraction methods and pair with gas, subcritical and supercritical fluid chromatography technologies that operate within the pressure and temperature parameters of the SFI. The SFI can operate up to 200 degrees celsius and 5000 psi. This interface technology allows for an inline oil extraction and chromatographic separation, the SFI can pair extraction and chromatography with the same solvent in different mobile phases, whereas the extraction can be performed using CO.sub.2 as a solvent in sub-critical phase and the SFI can receive the subcritical solution and then increase pressure and/or temperature to achieve supercritical state as required for injection into supercritical fluid chromatography technologies. The SFI coupling between SFE and SFC can to extract and refine cannabinoids from the cannabis industrious, hemp, plant and can also be applied to improve efficiency in an industry that extracts and refines oils, through chromatography, from organic materials using a gas, or sub/supercritical fluid as a solvent and mobile phase.

The present invention provides a dynamic interface system between an extraction device and a chromatographic purification device for separating and purifying substance(s) from a mixture or matrix. One embodiment is the Supercritical Fluid Interface (“SFI”) between Supercritical Fluid Extraction (“SFE”), and Supercritical Fluid Chromatography (“SFC”). The SFI is capable of interfacing; gas, subcritical and supercritical fluid extraction methods and pair with gas, subcritical and supercritical fluid chromatography technologies that operate within the pressure and temperature parameters of the SFI. The SFI can operate up to 200 degrees celsius and 5000 psi. This interface technology allows for an inline oil extraction and chromatographic separation, the SFI can pair extraction and chromatography with the same solvent in different mobile phases, whereas the extraction can be performed using CO.sub.2 as a solvent in sub-critical phase and the SFI can receive the subcritical solution and then increase pressure and/or temperature to achieve supercritical state as required for injection into supercritical fluid chromatography technologies. The SFI coupling between SFE and SFC can to extract and refine cannabinoids from the cannabis industrious, hemp, plant and can also be applied to improve efficiency in an industry that extracts and refines oils, through chromatography, from organic materials using a gas, or sub/supercritical fluid as a solvent and mobile phase.

A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester that has been produced using as a feedstock oil a fat or oil that contains highly unsaturated fatty acids as constituent fatty acids and which has been reduced in the contents of environmental pollutants, wherein among the dioxins contained, polychlorinated dibenzoparadioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are contained in amounts of less than 0.05 pg-TEQ/g and coplanar PCBs (Co-PCBs) in amounts of less than 0.03 pg-TEQ/g. Also disclosed is a method for producing the highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester by the steps of removing free fatty acids and environmental pollutants by thin-film distillation from a feedstock oil, ethyl esterifying the resulting fat or oil, and refining the same by rectification and column chromatography.

A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester that has been produced using as a feedstock oil a fat or oil that contains highly unsaturated fatty acids as constituent fatty acids and which has been reduced in the contents of environmental pollutants, wherein among the dioxins contained, polychlorinated dibenzoparadioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are contained in amounts of less than 0.05 pg-TEQ/g and coplanar PCBs (Co-PCBs) in amounts of less than 0.03 pg-TEQ/g. Also disclosed is a method for producing the highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester by the steps of removing free fatty acids and environmental pollutants by thin-film distillation from a feedstock oil, ethyl esterifying the resulting fat or oil, and refining the same by rectification and column chromatography.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.